Recombinant Human Collagen Type III Improves Hypertrophic Scarring by Regulating the Ratio of Type I/III Collagen.

This article focuses on the development and evaluation of recombinant human collagen type III (RHC3) as a therapeutic agent to improve hypertrophic scarring by modulating collagen composition. RHC3, produced via recombinant DNA technology, was shown to be highly homologous to natural human type III collagen, biocompatible, and capable of entering fibroblasts where it promoted the synthesis of natural type III collagen, thereby reducing the type I/III collagen ratio associated with hypertrophic scar formation. In a rabbit ear scar model, local injection of RHC3 significantly improved scar appearance and decreased the type I/III collagen ratio, as assessed by the Vancouver Scar Scale and biochemical analyses. These findings suggest that RHC3 may offer a novel clinical approach for scar prevention and treatment, although further mechanistic studies are needed.